Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA.
Orbit. 2023 Dec;42(6):571-578. doi: 10.1080/01676830.2022.2151628. Epub 2022 Dec 9.
To objectively measure the blink rate in patients with blepharospasm managed by botulinum toxin type-A injections.
In this prospective, non-interventional case series, the complete blink rates of subjects were measured before incobotulinumtoxina injection and at follow-up within 4 weeks using slow-motion video-taping. Additionally, subjects graded the frequency of blinking, the severity of light-sensitivity, and the severity and frequency of dry eye symptoms on a categorical visual analog scale. The results are reported as median (range).
Ten subjects were enrolled, with nine females. The total duration of treatment was 70 (5-116) months with total of 27.5 (2-51) injections. The subjects were grouped as short-time (<52w) or long-time (>52w) treatments. The median age, follow-up time, and injected doses were 73.5 (49-81) years, 21 (14-28) days, and 38 (8-47) units, respectively, with no significant difference between groups. The total complete blinks per minute before incobotulinumtoxina injection was 39 (23-64) which decreased to 18.5 (1-60) at follow-up (p = 0.004). The average change in complete blink rate was -67.4 ± 23.7% in long-time and -45.2 ± 31.2% in short-time groups (mean ± SD, p = 0.01). The total self-graded frequency of blinking and light-sensitivity decreased significantly at follow-up (p = 0.004, p = 0.047, respectively). Similar patterns of subject reported grades were seen in both groups.
Videotaping is a low-cost method for objective measurement of blink rate in blepharospasm patients after incobotulinumtoxina injection. There was a significant reduction in blink rate after incobotulinumtoxina injections with higher percentage of change in the long-time treatment group. Incobotulinumtoxina injection also significantly improves subjective photophobia.
客观测量肉毒毒素 A 注射治疗眼睑痉挛患者的眨眼频率。
在这项前瞻性、非干预性病例系列研究中，使用慢动作录像带在 incobotulinumtoxina 注射前和 4 周内的随访中测量受试者的完整眨眼率。此外，受试者使用分类视觉模拟量表对眨眼频率、畏光严重程度以及干眼症状的严重程度和频率进行评分。结果以中位数（范围）表示。
共纳入 10 例受试者，均为女性。总治疗时间为 70（5-116）个月，共注射 27.5（2-51）次。受试者分为短期（<52w）和长期（>52w）治疗组。中位年龄、随访时间和注射剂量分别为 73.5（49-81）岁、21（14-28）天和 38（8-47）单位，组间无显著差异。 incobotulinumtoxina 注射前每分钟总完整眨眼次数为 39（23-64），随访时降至 18.5（1-60）（p=0.004）。长期组完整眨眼率平均变化为-67.4±23.7%，短期组为-45.2±31.2%（均值±标准差，p=0.01）。随访时，眨眼和畏光的总自评频率均显著降低（p=0.004，p=0.047）。两组受试者报告的评分均呈现出相似的模式。
录像带是一种测量 incobotulinumtoxina 注射后眼睑痉挛患者眨眼率的低成本方法。 incobotulinumtoxina 注射后眨眼率显著降低，长期治疗组变化百分比更高。 incobotulinumtoxina 注射还显著改善了主观畏光。
